Literature DB >> 7435199

The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve.

P Tfelt-Hansen, J H Eickhoff, J Olesen.   

Abstract

Ergotamine tartrate (0.5 mg/70 kg) was given intravenously to 17 migraine patients. Arm, finger, ankle and big toe systolic blood pressures were measured with strain gauge technique for up to 4 hours and again after 22 hours. Systolic arm blood pressure increased transiently (duration less than 3 hours). Peripheral systolic blood pressures decreased in all patients (for toes a few to 55 mmHg) and at 22 hours well sustained decreases were still found. Further 10 migraine patients received 2-4 mg ergotamine tartrate as suppositories and peripheral systolic blood pressures were measured for 3 days. A decrease in peripheral systolic blood pressure was found after 24 hours but had disappeared after 48 hours. Contrary to common belief the present study investigating the effect of ergotamine directly on arteries has shown a long duration of its vasoconstrictory effect. Thus the effect of a single dose of ergotamine on the arteries should be followed for days.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7435199     DOI: 10.1111/j.1600-0773.1980.tb01855.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  9 in total

1.  The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects.

Authors:  Peer Tfelt-Hansen; Kaj Seidelin; Michael Stepanavage; Christopher Lines
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 2.  Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.

Authors:  P Tfelt-Hansen; P De Vries; P R Saxena
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Bioavailability of sublingual ergotamine.

Authors:  P Tfelt-Hansen; L Paalzow; J J Ibraheem
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

Review 4.  Intranasal medications for the treatment of migraine and cluster headache.

Authors:  Alan M Rapoport; Marcelo E Bigal; Stewart J Tepper; Fred D Sheftell
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

6.  Ergotamine, flunarizine and sumatriptan do not change cerebral blood flow velocity in normal subjects and migraneurs.

Authors:  H C Diener; C Peters; M Rudzio; A Noe; J Dichgans; R Haux; R Ehrmann; P Tfelt-Hansen
Journal:  J Neurol       Date:  1991-08       Impact factor: 4.849

7.  Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Nitroglycerin for ergotism. Experimental studies in vitro and in migraine patients and treatment of an overt case.

Authors:  P Tfelt-Hansen; J R Ostergaard; I Gøthgen; E Jacobsen; J P Rasmussen; B Husum
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 9.  Ergotamine and dihydroergotamine: a review.

Authors:  Marcelo E Bigal; Stewart J Tepper
Journal:  Curr Pain Headache Rep       Date:  2003-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.